Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial

Описание к видео Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial

Jorge Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a pivotal phase II trial that investigated the oral pan-BCR-ABL inhibitor ponatinib for patients with refractory chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia.

To read more, visit http://www.onclive.com/onclive-tv/Dr-...

Комментарии

Информация по комментариям в разработке